ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,928.31
0.19%
US Tech 100
20,136.00
0.05%
Dow Jones
43,782.25
0.86%
Brent Oil
73.40
0.77%
Bitcoin
97,164.63
2.97%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kronos Bio Inc (KRON) Quote

Kronos Bio Inc

Kronos Bio Inc (KRON)

Kronos Strategy
0.8977
0.0377
( 4.38% )
Updated: 11:32:01
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.8977
Bid
0.8854
Ask
0.91
Volume
53,549
0.8511 Day's Range 0.919
0.69 52 Week Range 1.60
Market Cap
54.168M
Previous Close
0.86
Open
0.877
Last Trade
6
@
0.909999
Last Trade Time
11:41:43
Financial Volume
$ 47,051
VWAP
0.878647
Average Volume (3m)
106,487
Shares Outstanding
60,340,918
Dividend Yield
-
PE Ratio
-0.49
Earnings Per Share (EPS)
-1.87
Revenue
6.29M
Net Profit
-112.67M

About Kronos Bio Inc

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kronosbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Kronos Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KRON. The last closing price for Kronos Bio was $0.86. Over the last year, Kronos Bio shares have traded in a share price range of $ 0.69 to $ 1.60.

Kronos Bio currently has 60,340,918 shares outstanding. The market capitalization of Kronos Bio is $51.89 million. Kronos Bio has a price to earnings ratio (PE ratio) of -0.49.

Ask ADVFN Intelligence (AI)

KRON Latest News

More News

Form EFFECT - Notice of Effectiveness

November 15 2024
Edgar (US Regulatory)

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo...

November 14 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 13 2024
Edgar (US Regulatory)

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio...

November 13 2024
GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933

November 07 2024
Edgar (US Regulatory)

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place...

November 05 2024
GlobeNewswire Inc.

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...

October 23 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

October 15 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 15 2024
Edgar (US Regulatory)

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking...

October 09 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0275993.171930614950.8701010.9190.84724940.85124436CS
4-0.0723-7.453608247420.9710.81672330.8732802CS
12-0.0923-9.323232323230.991.080.81064870.91953639CS
26-0.1423-13.68269230771.041.60.692285501.03261817CS
52-0.2723-23.27350427351.171.60.692585951.07610759CS
156-14.2923-94.090190915115.1915.80.692953553.18176839CS
260-27.3923-96.826793920128.2939.6050.692781598.4410328CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 2.0002
(104.10%)
109.68M
CRNCCerence Inc
$ 4.83
(71.28%)
34.81M
IBGInnovation Beverage Group Limited
$ 1.135
(43.45%)
8.84M
QUBTQuantum Computing Inc
$ 5.0514
(37.27%)
90.59M
SPAISafe Pro Group Inc
$ 4.2701
(33.44%)
38.86M
GLXGGalaxy Payroll Group Ltd
$ 1.68
(-57.03%)
892.74k
PYXSPyxis Oncology Inc
$ 2.07
(-45.81%)
9.55M
KURAKura Oncology Inc
$ 10.08
(-36.64%)
7.96M
BLRXBioLineRx Ltd
$ 0.3545
(-34.98%)
6.17M
SHOTWSafety Shot Inc
$ 0.1001
(-33.27%)
2.5k
CDTConduit Pharmaceuticals Inc
$ 0.111001
(20.26%)
496.04M
NVDANVIDIA Corporation
$ 145.1021
(-0.54%)
205.78M
AKTSAkoustis Technologies Inc
$ 0.1003
(15.15%)
184.24M
ELABElevai Labs Inc
$ 0.0202
(-5.61%)
174.72M
WORXSCWorx Corporation
$ 2.0002
(104.10%)
108.78M

KRON Discussion

View Posts
Monksdream Monksdream 3 months ago
KRON under $2
👍️0
Monksdream Monksdream 4 months ago
KRON under $2
👍️0
PonkenPlonken PonkenPlonken 4 months ago
Check CEO CV, super smart man that helped build Gilead before moving on to work on KRON. Recently he bought 8 million shares of common stock. I think its time to listen to whats being said. Chart sees clean breakout.

Probably the only promising CDK9 out there
👍️0
glenn1919 glenn1919 4 months ago
KRON.................................https://stockcharts.com/h-sc/ui?s=KRON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
KRON under $2
👍️0
glenn1919 glenn1919 8 months ago
KRON.................................https://stockcharts.com/h-sc/ui?s=KRON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
KRON under $2
👍️0
glenn1919 glenn1919 8 months ago
KRON....................................https://stockcharts.com/h-sc/ui?s=KRON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 months ago
KRON under $2
👍️0
Monksdream Monksdream 1 year ago
KRON new 52 week low
👍️0
Monksdream Monksdream 1 year ago
KRON new 52 week low
👍️0

Your Recent History

NASDAQ
KRON
Kronos Bio
EU
CA10L
CAC 40 X10 Leverage Net ...
BOV
TAEE4
TAESA PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved